RE:Questions for serious people, clowns please stay away Quick answer:
Nasdaq IBB got smoked in 2016 but has since made a bit of a recovery. We face a situation where there is a firm belief of a dilutive financing in the near future plus lack of institutional investment in Biotech perhaps due to hangover from CXR and VRX. I don't know the firm numbers but I'm sure the outstanding share number has increased in the last 18 months, irrelevant considering clinical developments in my opinion. Technicals pointing to some sort of major move (up or down) as Bollingers Bands are squeezing hard, hopefully moves in our favour!
Garth